In Depth Focus: Outsourcing
CRO Benchmark Report
Highlights from GlobalData's CRO Benchmark Report
By Adam M. Dion
Fall 2013

The biopharmaceutical industry is currently facing significant headwinds. The blockbuster era is over, development costs are skyrocketing, uncertainty exists around regulatory and reimbursement, patent cliffs, generic erosion and a sluggish global economy all have industry executives losing sleep at night.

To respond to these pressures, biopharmaceutical companies have been changing the way they approach virtually every aspect of their business, including research and development. To remain competitive, drug makers are intensely focusing on generating more value and productivity out of every dollar spent on R&D.

The challenge of accelerating pharmaceutical product development while controlling costs creates a difficult balancing act for industry executives. Through the use of strategic outsourcing with third-party vendors, drug makers can maximise their internal resources while at the same time entering into risk-sharing agreements with CROs to generate significant cost savings.

The total combined peer group revenue from these leading CRO companies increased 10.2% year-to-year, from $12.4 billion in 2011 to..........